Literature DB >> 7684431

Contribution of direct and indirect recognition pathways to T cell alloreactivity.

Z Liu1, Y K Sun, Y P Xi, A Maffei, E Reed, P Harris, N Suciu-Foca.   

Abstract

T cells from an HLA-DR11/DR12 responder were stimulated in mixed lymphocyte culture with cells carrying the DR1 antigen. After priming, T cells proliferated in response to both DR1-positive-stimulating cells and a peptide derived from a polymorphic region of the HLA-DR beta 1*0101 chain presented by responder's antigen-presenting cells (APC). The dominant epitope recognized by the primed T cells corresponded to residue 21-42 and was presented by the responder's HLA-DR12 antigen. The DR1 peptide-reactive T cells express T cell receptor V beta 3. The results demonstrate that allopeptides derived from the processing and presentation of donor major histocompatibility complex molecules by host-derived APC trigger alloreactivity. The frequency of T cells engaged in the indirect pathway of allorecognition is about 100-fold lower than that of T cells participating in the direct recognition of native HLA-DR antigen. However, indirect allorecognition may play an important role in chronic allograft rejection, a phenomenon that is mediated by the activation of T helper cells and of alloantibody-producing B cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684431      PMCID: PMC2191044          DOI: 10.1084/jem.177.6.1643

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

Review 1.  Processed MHC class I alloantigen as the stimulus for CD4+ T-cell dependent antibody-mediated graft rejection.

Authors:  J A Bradley; A M Mowat; E M Bolton
Journal:  Immunol Today       Date:  1992-11

2.  T cell recognition of allopeptides in context of syngeneic MHC.

Authors:  Z Liu; N S Braunstein; N Suciu-Foca
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

3.  Molecular mimicry in liver disease.

Authors:  A K Burroughs; P Butler; M J Sternberg; H Baum
Journal:  Nature       Date:  1992-07-30       Impact factor: 49.962

4.  Allelic variation in the DR subregion of the human major histocompatibility complex.

Authors:  J I Bell; D Denney; L Foster; T Belt; J A Todd; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

5.  Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences.

Authors:  J Sprent; M Schaefer; D Lo; R Korngold
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

6.  Effector cells in allelic H-2 class I-incompatible skin graft rejection.

Authors:  T Ichikawa; E Nakayama; A Uenaka; M Monden; T Mori
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

7.  T cell recognition of self-human histocompatibility leukocyte antigens (HLA)-DR peptides in context of syngeneic HLA-DR molecules.

Authors:  Z Liu; Y K Sun; Y P Xi; P Harris; N Suciu-Foca
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

8.  Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.

Authors:  J Fangmann; R Dalchau; J W Fabre
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

9.  Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection.

Authors:  A S Rosenberg; T Mizuochi; S O Sharrow; A Singer
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

10.  Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection.

Authors:  G Benichou; P A Takizawa; C A Olson; M McMillan; E E Sercarz
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  34 in total

1.  CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II.

Authors:  B A Pietra; A Wiseman; A Bolwerk; M Rizeq; R G Gill
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 2.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Antigenicity and immunogenicity of allogeneic retinal transplants.

Authors:  N G Anosova; B Illigens; F Boisgérault; E V Fedoseyeva; M J Young; G Benichou
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 4.  Immunology of corneal transplantation.

Authors:  W H Constad; K Taraschanskiy
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

5.  Cross-tolerance of recipient-derived transforming growth factor-beta dendritic cells.

Authors:  M-M Tiao; L Lu; L-T Huang; C-D Liang; C-L Chen; R Tao; J J Fung; S Qian
Journal:  Transplant Proc       Date:  2007 Jan-Feb       Impact factor: 1.066

6.  T cell receptor biases and clonal proliferations among lung transplant recipients with obliterative bronchiolitis.

Authors:  S R Duncan; V Valentine; M Roglic; D J Elias; K W Pekny; J Theodore; D H Kono; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

7.  T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice.

Authors:  A Valujskikh; D Matesic; A Gilliam; D Anthony; T M Haqqi; P S Heeger
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

Review 8.  [Immunologic, alloantigen-dependent factors in chronic graft rejection].

Authors:  C Barth; J Stachowski; A von Menges; P Lammerding; C A Baldamus
Journal:  Med Klin (Munich)       Date:  1998-01-15

9.  Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II.

Authors:  Thomas Fehr; Fabienne Haspot; Joshua Mollov; Meredith Chittenden; Timothy Hogan; Megan Sykes
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Dendritic cells stimulated with Actinobacillus actinomycetemcomitans elicit rapid gamma interferon responses by natural killer cells.

Authors:  T Kikuchi; C L Hahn; S Tanaka; S E Barbour; H A Schenkein; J G Tew
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.